Melena, Orthostasis, and Antithrombotic Tradeoffs

Learning objectives#

• Recognize clinically important upper gastrointestinal bleeding before a dramatic supine blood-pressure fall or nadir hemoglobin appears.
• Resuscitate in parallel with risk assessment, medication reconciliation, and preparation for endoscopic source control.
• Distinguish temporary interruption, emergency reversal, and permanent discontinuation of antithrombotic therapy.
• Balance recurrent bleeding against stroke and coronary risk when deciding whether and when to resume anticoagulation or antiplatelet therapy.
• Prevent recurrence through ulcer-cause treatment, medication simplification, confirmed Helicobacter pylori eradication, and a coordinated handoff.

Initial presentation#

The analysis opens with Samuel, a 78-year-old man who arrives after nearly fainting in his bathroom. For three days his stool has been black and sticky, but he assumed the color came from a bismuth-containing stomach remedy. This morning he became sweaty and lightheaded when standing, lowered himself to the floor, and called his son. He has not vomited blood. He reports burning discomfort high in the abdomen and unusual fatigue. He denies bright red rectal bleeding, severe chest pain, or a focal neurologic symptom.

His history includes atrial fibrillation, a transient ischemic attack five years earlier, hypertension, stage 3 chronic kidney disease, and coronary artery disease. A drug-eluting coronary stent was placed three years ago after a non-ST-elevation myocardial infarction. He has had no recurrent ischemic event or stent thrombosis. His medicines include a direct oral factor Xa inhibitor for atrial fibrillation and aspirin. He took both on the morning of presentation. For the past two weeks, he has also used a nonsteroidal anti-inflammatory drug several times daily for back pain after gardening. He does not take a proton-pump inhibitor.

Samuel says no one has revisited why he takes both a blood thinner and aspirin. Different specialists renew them. He believes the anticoagulant protects the stent and aspirin prevents atrial fibrillation. He occasionally misses the evening anticoagulant because of cost but took it consistently during the current week. He has no known cirrhosis, varices, prior ulcer, gastrointestinal cancer, or previous major bleeding. He drinks one beer on some weekends and uses no tobacco.

At triage, he is pale but alert. Supine blood pressure is 112/68 mm Hg and pulse 96 per minute. When assisted to sit, blood pressure falls to 86/52 mm Hg, pulse rises to 118, and he becomes clammy and nauseated. The maneuver is stopped and he is returned supine. Respiratory rate is 21 per minute, oxygen saturation is 96 percent on room air, and temperature is normal. Extremities are cool with delayed capillary refill. The abdomen is soft with mild epigastric tenderness and no guarding. Rectal examination confirms black, tarry stool. There is no ascites, jaundice, or focal neurologic deficit.

Initial hemoglobin is 8.2 g/dL, down from 13.4 g/dL four months earlier. Platelets are normal. Urea is disproportionately elevated relative to creatinine, which is slightly above baseline. Lactate is elevated. The international normalized ratio is near the reference range. A trainee takes that coagulation result as evidence that the factor Xa inhibitor is no longer active and suggests waiting for the next day's endoscopy because the supine blood pressure is above 100 mm Hg.

That proposal misses three points. Routine prothrombin-time measures do not reliably exclude clinically relevant factor Xa inhibitor activity. Orthostatic collapse, cool extremities, lactate elevation, major hemoglobin change, and ongoing melena indicate important blood loss despite the supine value. Resuscitation, antithrombotic decisions, and preparation for source control must begin now.

Problem representation#

This is an older adult with melena, epigastric discomfort, orthostatic hypotension, impaired perfusion, acute anemia, and a high pre-endoscopic bleeding-risk profile while taking an oral factor Xa inhibitor, aspirin, and a recently added nonsteroidal anti-inflammatory drug. He has substantial thromboembolic risk from atrial fibrillation and prior transient ischemic attack, but the continued coronary indication for aspirin three years after uncomplicated stenting is uncertain.

The leading diagnosis is major nonvariceal upper gastrointestinal bleeding, most likely an NSAID-associated or Helicobacter pylori-associated peptic ulcer, amplified by antithrombotic therapy. Immediate priorities are circulation and source control. The anticoagulant and aspirin questions must be separated into three phases: what to hold during active hemorrhage, whether a reversal or hemostatic agent is justified, and which therapies should be resumed after control.

The case is not solved by labeling all antithrombotics harmful. Failure to restart necessary anticoagulation exposes Samuel to preventable stroke. Failure to question unnecessary combination therapy exposes him to repeat bleeding. The correct endpoint is the minimum effective antithrombotic regimen for his actual indications, not automatic restoration of the admission list.

Prioritized differential#

Peptic ulcer bleeding#

Melena, epigastric discomfort, nonsteroidal anti-inflammatory exposure, aspirin, and anticoagulation make a gastric or duodenal ulcer most likely. Helicobacter pylori may coexist. A high-risk ulcer stigma would explain ongoing bleeding and provide an endoscopic treatment target. Medication exposure amplifies hemorrhage but does not prove ulcer location or exclude malignancy.

Erosive gastroduodenal or esophageal disease#

Erosive gastritis, duodenitis, or esophagitis can bleed, particularly with antithrombotics. These lesions often cause less focal arterial bleeding than a high-risk ulcer but can still be clinically important. Endoscopy distinguishes them and assesses whether intervention is needed.

Variceal or portal-hypertensive bleeding#

There is no known liver disease, ascites, thrombocytopenia, or stigmata of portal hypertension. Variceal hemorrhage is less likely but remains a high-consequence alternative if history, examination, imaging, or endoscopy changes the probability. Suspected variceal bleeding would alter vasoactive, antibiotic, and endoscopic pathways.

Upper gastrointestinal malignancy#

Gastric or esophageal cancer can ulcerate and bleed. Weight loss, progressive dysphagia, iron deficiency predating the event, early satiety, and family history would increase concern. Endoscopic visualization and biopsy planning matter, although biopsy may be deferred at an actively bleeding treatment site.

Vascular and structural lesions#

Dieulafoy lesion, angioectasia, portal hypertensive gastropathy, gastric antral vascular ectasia, and a Mallory-Weiss tear can produce upper gastrointestinal bleeding. The absence of forceful vomiting makes a tear less likely. Aortoenteric fistula must be considered in a person with prior aortic grafting and a herald bleed; Samuel has no such history.

Small-bowel or right-colonic bleeding#

Melena usually points to an upper source, but slow small-bowel or proximal colonic bleeding can appear black. If upper endoscopy is negative or bleeding continues without explanation, the pathway broadens to computed tomographic angiography during active significant bleeding, colon evaluation, capsule study, or enteroscopy according to stability and local expertise.

Nonbleeding causes of black stool with another cause of shock#

Iron and bismuth can darken stool, but the tarry character, hemoglobin decline, urea pattern, and orthostasis establish genuine bleeding. Sepsis, arrhythmia, adrenal crisis, and dehydration could contribute to hypotension, but they do not explain the full pattern as well.

Focused history and examination#

The focused assessment estimates hemorrhage, identifies the likely source, determines current antithrombotic effect, and retrieves the indications that will shape restart decisions.

• Bleeding phenotype: Ask about first black stool, frequency, hematemesis, coffee-ground material, bright blood, syncope, chest symptoms, dyspnea, urine output, and prior episodes. Stool color from iron or bismuth does not exclude simultaneous bleeding.
• Hemodynamic impact: Repeat mental status, skin perfusion, pulse, blood pressure, respiratory status, urine output, and symptoms. Orthostatic testing should not be repeatedly provoked in an unstable patient.
• Medication chronology: Verify anticoagulant name, last ingestion, prescribed schedule, missed doses, kidney function, antiplatelets, nonsteroidal anti-inflammatory drugs, glucocorticoids, selective serotonin reuptake inhibitors, supplements, and alcohol. Pharmacy fill history can resolve uncertainty.
• Indications and duration: Document atrial fibrillation stroke factors, prior embolism, valve disease, date and reason for coronary intervention, stent thrombosis history, recent acute coronary syndrome, and the cardiologist's intended antiplatelet duration.
• Liver and portal clues: Review liver disease, viral hepatitis, alcohol, ascites, prior varices, thrombocytopenia, and encephalopathy.
• Ulcer and malignancy clues: Ask about prior Helicobacter pylori testing, dyspepsia, ulcer, weight loss, early satiety, dysphagia, family history, and previous endoscopy.
• Transfusion considerations: Ask about coronary ischemia, heart failure, prior transfusion reactions, known antibodies, and patient preferences or religious limits concerning blood products.

Samuel says avoiding another stroke matters most because he cared for his brother after a disabling stroke. He is also afraid of transfusion after hearing about infection decades ago. The clinician acknowledges both concerns and explains contemporary screening, expected benefit, and alternatives in the context of active blood loss.

Diagnostic strategy#

Resuscitate before chasing a perfect score#

Two reliable intravenous access sites are established, blood is typed and crossmatched, and continuous monitoring begins. A balanced crystalloid is used judiciously while blood availability and response are assessed. Excessive crystalloid can dilute clotting factors, worsen edema, and create a misleading hemoglobin change. Red-cell transfusion follows a generally restrictive strategy, but the decision includes active shock, symptoms, ongoing bleeding, coronary disease, and trajectory rather than a threshold alone.

Serial complete blood count, metabolic panel, liver tests, lactate, and clinically appropriate coagulation studies are obtained. Hemoglobin may initially understate acute loss before equilibration. The urea rise supports an upper source but is not diagnostic. Platelet count and fibrinogen matter if bleeding is severe or a massive-transfusion pathway is activated.

Routine international normalized ratio or activated partial thromboplastin time cannot reliably quantify a direct oral anticoagulant. A drug-specific calibrated anti-factor Xa level, when rapidly available, can help establish clinically relevant activity. If it is unavailable, last dose, kidney function, interactions, and time remain central. Testing must not delay resuscitation or endoscopy.

Use risk scores for disposition, not as substitutes for judgment#

The Glasgow-Blatchford score uses clinical and laboratory findings to identify very-low-risk patients who may be suitable for outpatient care. Samuel is clearly not in that group because he has melena, syncope or near-syncope, orthostatic hypotension, urea elevation, and substantial anemia. Calculating the score can standardize communication, but it adds no permission to delay care in an unstable patient.

Post-endoscopic scores can inform prognosis, yet no score reliably predicts every rebleed or death. The patient's repeated physiology and endoscopic stigma remain decisive. A nasogastric aspirate is not routinely required to prove an upper source and a negative aspirate would not exclude it.

Prepare for timely endoscopy and alternative source control#

Gastroenterology is contacted during resuscitation. Upper endoscopy is planned within 24 hours after initial hemodynamic stabilization and sooner when ongoing severe bleeding requires urgent source control and airway planning permits safe treatment. "Urgent" does not mean sedating a patient before the circulation is supported; "resuscitate first" does not mean waiting until every number is normal.

An intravenous proton-pump inhibitor may be started before endoscopy according to the local pathway, recognizing that pre-endoscopic therapy can reduce high-risk stigmata and need for endoscopic treatment without clearly replacing endoscopy or improving every major outcome. After successful hemostasis of a high-risk ulcer, intensive acid suppression is recommended. Exact prescribing follows the verified protocol.

If hemorrhage continues despite endoscopy, repeat endoscopic therapy, transcatheter arterial embolization, and surgery are considered in sequence according to lesion, expertise, and stability. Computed tomographic angiography can help localize active bleeding when endoscopy is nondiagnostic or another source is suspected.

Progressive results and interpretation#

Despite initial crystalloid and blood support, Samuel passes another large melena stool. Supine blood pressure falls to 92/58 mm Hg and lactate rises. Repeat hemoglobin is 7.4 g/dL. Electrocardiography shows atrial fibrillation without acute ST elevation. High-sensitivity troponin is mildly elevated but stable on repeat, consistent with physiologic stress rather than proving acute coronary thrombosis.

The factor Xa inhibitor was taken six hours before arrival, and kidney impairment may prolong exposure. This is major bleeding with likely clinically relevant anticoagulant effect. The team holds the anticoagulant and aspirin and stops the nonsteroidal anti-inflammatory drug. Whether to reverse is discussed immediately with gastroenterology, hematology or pharmacy, and the resuscitation team.

Samuel responds to transfusion and targeted resuscitation, perfusion improves, and endoscopy is promptly available. Because bleeding is not continuing at a life-threatening rate after stabilization and source control is imminent, the team does not give a reversal agent. This decision is documented as contingent, not ideological. If shock had persisted, transfusion need accelerated, or endoscopic control were unavailable, specific reversal or a prothrombin-complex strategy would have been considered under the local major-bleeding protocol.

Endoscopy shows a duodenal ulcer with a nonbleeding visible vessel and old blood in the stomach. There are no varices. Combination endoscopic hemostasis is applied; injection is not used as sole definitive therapy. No other bleeding lesion is found. Intensive proton-pump inhibition follows. Gastric testing is positive for Helicobacter pylori.

Over the next 48 hours, blood pressure and lactate normalize, stool gradually lightens, and hemoglobin stabilizes without further transfusion. There is no recurrent chest discomfort, neurologic deficit, or hematemesis. The ulcer source, successful hemostasis, and clinical stability permit the conversation to move from interruption to prevention and restart.

Cardiology reviews the coronary record. The stent was placed three years earlier, there has been no thrombosis or recurrent acute coronary syndrome, and no separate current indication for aspirin is identified. Contemporary atrial fibrillation guidance generally favors oral anticoagulant monotherapy beyond the early period after uncomplicated coronary revascularization in stable coronary disease because combination therapy increases bleeding. Aspirin is therefore not resumed. This is different from withholding aspirin that remains necessary for secondary prevention; the team has determined that the current combination is unnecessary.

Samuel's prior transient ischemic attack and other stroke factors create high thromboembolic risk. Once endoscopic hemostasis is secure, hemoglobin is stable, and no rebleeding occurs, the factor Xa inhibitor is restarted during the recovery period before discharge. Kidney function and label criteria are checked to confirm the appropriate long-term regimen. The choice is documented jointly rather than left as "hold until primary care decides."

Management plan#

Support circulation and oxygen delivery#

Resuscitation uses repeated clinical targets: mentation, perfusion, blood pressure, urine output, lactate trend, symptoms, and ongoing blood loss. Transfusion is not based on a single early hemoglobin. A restrictive strategy is appropriate for many upper gastrointestinal bleeds, but active shock or myocardial ischemia can justify a different decision. Platelets or plasma are not given simply because the patient is bleeding; their use depends on measured deficits, massive hemorrhage, or a specific reversal pathway.

Routine tranexamic acid is not used. The large HALT-IT trial did not show a reduction in death from gastrointestinal bleeding and identified harm signals, so trauma protocols should not be imported automatically into gastrointestinal hemorrhage.

Achieve and protect source control#

High-risk ulcer stigmata receive evidence-based endoscopic therapy. Epinephrine injection, if used, is combined with another modality rather than used alone. After hemostasis, intensive proton-pump inhibition reduces rebleeding risk. Recurrent clinical bleeding prompts repeat endoscopy and, if that fails, transcatheter embolization or surgery according to expertise and anatomy.

Helicobacter pylori is treated with a guideline-concordant regimen selected for allergy history, prior antibiotic exposure, local resistance, interactions, and availability. Exact agents and doses are not reproduced here. Eradication is confirmed with an appropriate nonserologic test after treatment and after interfering medicines are held for the required interval. Symptoms alone cannot confirm cure.

The nonsteroidal anti-inflammatory drug is stopped. Alternatives for back pain include assessment for red flags, physical therapy, topical options, activity modification, and non-NSAID analgesic strategies appropriate to kidney and liver function. If an NSAID were ever unavoidable, the indication, lowest effective exposure, gastroprotection, and antithrombotic burden would require explicit review.

Separate interruption, reversal, and long-term necessity#

The oral anticoagulant is interrupted during active major bleeding. A reversal or hemostatic agent is reserved for life-threatening or uncontrolled bleeding when relevant anticoagulant effect is likely. ACC and gastroenterology guidance differ in emphasis because direct evidence is limited, reversal carries thrombotic and cost burdens, and many gastrointestinal sources can be controlled promptly. A local pathway should reconcile these recommendations before an emergency occurs.

Aspirin taken for secondary cardiovascular prevention is often continued or resumed promptly after hemostasis if it remains indicated. Stopping it for weeks can expose a high-risk patient to ischemic events. Samuel's case differs because cardiology confirms there is no ongoing need for aspirin in addition to anticoagulation. Permanent simplification follows indication review, not the bleeding event alone.

Anticoagulation restart weighs lesion control, rebleeding, hemoglobin stability, renal function, prior stroke, atrial fibrillation risk, and patient goals. A calendar date without these inputs is unsafe. Indefinite interruption is also unsafe. The plan names the agent, restart point, responsible clinician, and what would postpone or reverse the decision.

Correct anemia and restore function#

Iron status is evaluated after the acute phase, recognizing that transfusion and inflammation affect interpretation. Iron replacement is provided when indicated. Recovery includes orthostatic symptoms, mobility, falls, exertional tolerance, and cognition, not hemoglobin alone. Samuel receives assisted mobilization before discharge and a plan for repeat blood counts.

Escalation, referral, and safety net#

Immediate escalation is required for hematemesis with airway risk, shock, recurrent syncope, rapidly increasing transfusion requirement, ongoing large-volume melena or hematochezia, severe chest ischemia, new neurologic deficit, or failure of initial endoscopic control. Critical care, anesthesia, gastroenterology, interventional radiology, surgery, transfusion medicine, and cardiology are involved according to the evolving threat.

Recurrent bleeding after initial endoscopic hemostasis is not managed by adding indefinite transfusions alone. Repeat endoscopy is usually the next source-control step. Failure can lead to transcatheter arterial embolization and surgery. Local availability should be known early enough to arrange transfer before instability makes transport unsafe.

After discharge, black tarry stool with weakness, vomiting blood, red blood with dizziness, fainting, new chest pain, shortness of breath at rest, or a focal neurologic symptom requires emergency assessment. Mild darkening from iron may be expected if prescribed, but Samuel is taught that texture, symptoms, and uncertainty should prompt contact rather than self-diagnosis.

He should not independently stop or double the anticoagulant. A missed dose, dental procedure, fall with head injury, recurrent ulcer symptoms, or new medicine should trigger the written contact plan. Every clinician prescribing an anti-inflammatory, antiplatelet, or interacting drug should see the prior major bleed and current indication list.

Communication, shared decisions, and equity#

The clinician explains the competing risks without presenting them as an impossible choice: "The ulcer has been treated. The anticoagulant made the bleeding harder to stop, but it also protects you from stroke. We are removing aspirin because your heart team no longer finds a separate reason for it, treating the ulcer cause, and restarting the anticoagulant once the treated site is stable. That gives you stroke protection with less avoidable bleeding risk."

Samuel learns that aspirin does not treat atrial fibrillation and that his anticoagulant is not the main medicine protecting an old coronary stent. Correcting this mental model improves future adherence. The team uses teach-back: he explains which medicine is stopping, which is restarting, why, and whom to call before a procedure.

Cost is a clinical variable. Samuel's intermittent missed doses create stroke risk, and switching among antithrombotics based on monthly cash flow is unsafe. Pharmacy and social work evaluate coverage, assistance, refill synchronization, and lower-cost clinically suitable options. A choice that is pharmacologically ideal but unaffordable is not a reliable treatment.

Language, hearing, vision, and health literacy affect bleeding instructions. Large-print materials describe stool and vomit changes in plain terms. The team asks whether Samuel can reach a laboratory and who can accompany him if dizziness returns. His son joins the conversation with permission, but Samuel remains the decision-maker.

Transfusion concerns are handled respectfully with current information, not dismissal. If a patient declines blood products, acceptable alternatives and limits should be clarified early, and the source-control strategy may need additional urgency. Cultural beliefs, prior experiences, and mistrust can be discussed without delaying life-saving care.

Follow-up and contingencies#

The discharge handoff lists the ulcer location and stigma, endoscopic therapy, lowest and discharge hemoglobin, transfusions, Helicobacter pylori result, acid-suppression plan, kidney function, discontinued aspirin and NSAID, anticoagulant restart, and responsible follow-up clinicians. It includes the reasoning for oral anticoagulant monotherapy so a future medication reconciliation does not automatically restore aspirin.

Follow-up checks symptoms, stool, orthostasis, blood count, iron status, kidney function, medicine access, and adherence. Gastroenterology confirms Helicobacter pylori eradication and determines whether repeat endoscopy is needed based on ulcer location, healing concern, pathology, or recurrent symptoms. Primary care coordinates pain treatment and blood-pressure management. Cardiology reassesses coronary and atrial fibrillation indications if new ischemic events occur.

Contingency branches are explicit:

• Melena or hemoglobin decline recurs before anticoagulation restart: Reassess urgently for failed hemostasis and repeat source control; do not simply extend the hold without investigating.
• Bleeding recurs after restart: Establish severity, last dose, kidney function, and source; interrupt or reverse according to the major-bleeding pathway while preserving a plan to revisit stroke prevention.
• A new acute coronary syndrome or coronary intervention occurs: Antiplatelet requirements change and require cardiology-led balancing with anticoagulation and gastroprotection.
• Helicobacter pylori remains positive: Review adherence, prior antibiotics, susceptibility information when available, and use an evidence-based salvage regimen followed by another test of cure.
• Kidney function worsens: Reassess anticoagulant selection and label criteria, interacting medicines, volume status, and bleeding risk.
• No upper source had been found: Broaden the investigation to small bowel, colon, vascular lesions, and non-gastrointestinal sources according to the bleeding pattern.

The plan also includes fall recovery and gradual activity. Orthostasis that resolves in bed may return with showering or stairs. Safe mobility testing is part of readiness for discharge.

Reasoning traps and alternative pathways#

• Reassurance from a normal supine blood pressure: Compensated blood loss can produce orthostatic collapse and impaired perfusion before sustained hypotension appears.
• Reassurance from the first hemoglobin: Acute hemorrhage may not be fully reflected until redistribution and fluid equilibration occur.
• Using the international normalized ratio to rule out direct oral anticoagulant effect: Routine coagulation tests have limited sensitivity and depend on reagent and drug.
• Reversing every anticoagulated bleed: Reversal is for selected life-threatening or uncontrolled major bleeding, not a reflex for stable minor bleeding.
• Never reversing because endoscopy exists: Persistent shock with likely active drug effect may require reversal and source control in parallel.
• Applying a transfusion threshold without physiology: Coronary ischemia, shock, symptoms, and ongoing bleeding can change the decision.
• Using injection alone for a high-risk ulcer: Definitive endoscopic hemostasis requires an effective second modality when injection is used.
• Holding all antithrombotics indefinitely: The risk of stroke or coronary events persists while the gastrointestinal lesion heals.
• Automatically restoring the admission list: The bleed is an opportunity to remove duplicate or obsolete antithrombotic therapy.
• Treating Helicobacter pylori without confirming eradication: Symptoms and completed pills do not establish cure.
• Giving tranexamic acid because bleeding is severe: Evidence from gastrointestinal bleeding does not support routine use.

An alternative pathway would be needed if cirrhosis and variceal hemorrhage were suspected, because vasoactive therapy, antibiotics, and variceal endoscopic management would enter early. A patient with a mechanical heart valve, very recent venous thromboembolism, recent coronary stent, or recent acute coronary syndrome would have a different thrombosis profile. A negative upper endoscopy with continuing brisk bleeding would prompt vascular imaging or lower and small-bowel evaluation. A hemodynamically stable patient with a very-low-risk Glasgow-Blatchford score might be managed without admission, unlike Samuel.

Evidence limits and what could change#

Upper gastrointestinal bleeding guidelines broadly support early risk assessment, resuscitation, endoscopy after stabilization, endoscopic treatment of high-risk lesions, intensive acid suppression, and a generally restrictive transfusion approach. The certainty varies across specific interventions, and patients with active coronary ischemia, exsanguinating hemorrhage, or unusual comorbidity are often underrepresented in trials.

The landmark restrictive-transfusion trial showed improved outcomes with a restrictive strategy in its population, but important high-risk vascular groups were excluded. A numeric threshold should therefore guide rather than replace individualized oxygen-delivery assessment. More recent trials across other illnesses do not automatically answer the upper gastrointestinal bleeding question.

Evidence for direct oral anticoagulant reversal in gastrointestinal bleeding is limited. ACC guidance supports reversal for life-threatening or unresponsive major bleeding, while the ACG-CAG guideline is cautious about routine use of specific reversal agents or prothrombin complex concentrates because of low-certainty evidence. Institutions need a multidisciplinary pathway that accounts for availability, assay turnaround, thrombotic risk, cost, and access to rapid endoscopic control.

Antithrombotic resumption studies are largely observational and use different definitions of bleeding control, rebleeding, and thromboembolic risk. ESGE supports resuming needed anticoagulation as soon as bleeding is controlled, preferably within or soon after the first week according to risk. That window is a framework, not a substitute for the lesion, hemostasis, and patient-specific indication.

The aspirin continuation trial after ulcer bleeding was small but highlighted the possible mortality cost of prolonged withdrawal when aspirin is truly needed for secondary prevention. It does not imply that every patient should remain on aspirin forever. Current atrial fibrillation guidance supports anticoagulant monotherapy for many patients with stable coronary disease beyond the initial post-revascularization period, absent a special coronary indication.

Helicobacter pylori treatment continues to evolve with antibiotic resistance and new acid-suppression options. Regimen choice and test-of-cure timing should follow current regional guidance and individual antibiotic exposure. Future evidence may refine anticoagulant restart timing, reversal selection, endoscopic powders and clips, and risk models, but source control and indication review will remain central.

Key points#

• Melena with orthostatic symptoms and impaired perfusion is a significant bleed even when supine blood pressure is initially preserved.
• Resuscitation, anticoagulant assessment, and preparation for endoscopic source control proceed in parallel.
• Routine coagulation tests cannot reliably exclude direct oral anticoagulant activity.
• Reversal is selective; permanent discontinuation and temporary interruption are different decisions.
• Resume necessary stroke prevention after secure hemostasis, but do not automatically restore unnecessary aspirin or NSAID exposure.
• Treat and confirm eradication of Helicobacter pylori, simplify the medication list, and document exactly who owns follow-up.

Sources#

1. ACG Clinical Guideline on Upper Gastrointestinal and Ulcer Bleeding
2. ESGE Guideline on Nonvariceal Upper Gastrointestinal Hemorrhage Update 2021
3. NICE CG141 Acute Upper Gastrointestinal Bleeding Recommendations
4. International Consensus Group Recommendations for Nonvariceal Upper Gastrointestinal Bleeding
5. ACG CAG Guideline on Anticoagulants and Antiplatelets During Acute GI Bleeding
6. ACC Expert Consensus Pathway on Bleeding in Patients on Oral Anticoagulants
7. 2023 ACC AHA ACCP HRS Atrial Fibrillation Guideline
8. Transfusion Strategies for Acute Upper Gastrointestinal Bleeding Randomized Trial
9. HALT-IT Randomized Trial of Tranexamic Acid in Gastrointestinal Bleeding
10. International Prospective Comparison of Upper GI Bleeding Risk Scores
11. Continuation of Aspirin After Peptic Ulcer Bleeding Randomized Trial
12. ACG 2024 Helicobacter pylori Guideline Summary